Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA:600513)

Market Cap	6.45B +129.9%
Revenue (ttm)	2.60B +11.3%
Net Income	-43.60M
EPS	-0.15
Shares Out	285.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.09 (0.40%)
Ex-Dividend Date	Jun 23, 2025

Volume	2,446,401
Average Volume	12,618,922
Open	22.80
Previous Close	22.58
Day's Range	22.49 - 22.90
52-Week Range	8.30 - 31.58
Beta	0.55
RSI	57.93
Earnings Date	Apr 21, 2026

About SHA:600513

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprilite, danazol suppositories, and terfenadine tablets. It also provides urinary system drugs, including eprepitant tablets, terazosin tablets, and drotave...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 1,388
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600513

Financial Performance

In 2024, SHA:600513's revenue was 2.16 billion, a decrease of -0.63% compared to the previous year's 2.17 billion. Earnings were 84.16 million, a decrease of -37.66%.